Loading...
SVE
ENG
About Us
About Us
Close
InDex Pharmaceuticals in brief
CEO corner
Business model
Corporate governance
General meetings
Nomination committee
Board of directors
Work of the board of directors
Management
Remuneration and incentive programmes
Auditors
Articles of association
Advisory Board North America
Advisory Board Europe
Research & Development
Research & Development
Close
Technology platform & pipeline
Scientific articles
Cobitolimod
About ulcerative colitis and today's standard of care
A new opportunity with cobitolimod
Clinical studies
Phase III program CONCLUDE
Questions and answers on CONCLUDE
CONDUCT
The CONDUCT study
Study design
Frequently asked questions about CONDUCT
Ulcerative Colitis
Ulcerative Colitis
Close
About ulcerative colitis and today's standard of care
Living with ulcerative colitis - read patient stories
About cobitolimod
Phase III program CONCLUDE
About clinical trials
Additional information
Investors
Investors
Close
Invest in InDex Pharmaceuticals
The share
Dividend and dividend policy
Shareholders
InDex Pharmaceuticals on Nasdaq First North Growth Market
Financial reports
Presentations
Press releases
Subscribe
Financial calendar
Analysts
Prospectus archive
Certified Adviser
IR contact
Media
Media
Close
Press releases
Image bank
Subscribe
Media contact
Career
Career
Close
Career
Job openings
Open application
Contact
Contact
Close
IR contact
Media contact
Certified Adviser
Search for:
About Us
InDex Pharmaceuticals in brief
CEO corner
Business model
Corporate governance
General meetings
Nomination committee
Board of directors
Work of the board of directors
Management
Remuneration and incentive programmes
Auditors
Articles of association
Advisory Board North America
Advisory Board Europe
Research & Development
Technology platform & pipeline
Scientific articles
Cobitolimod
About ulcerative colitis and today’s standard of care
A new opportunity with cobitolimod
Clinical studies
Phase III program CONCLUDE
Questions and answers on CONCLUDE
CONDUCT
The CONDUCT study
Study design
Frequently asked questions about CONDUCT
Ulcerative Colitis
About ulcerative colitis and today’s standard of care
Living with ulcerative colitis – read patient stories
About cobitolimod
Phase III program CONCLUDE
About clinical trials
Additional information
Investors
Invest in InDex Pharmaceuticals
The share
Dividend and dividend policy
Shareholders
InDex Pharmaceuticals on Nasdaq First North Growth Market
Financial reports
Presentations
Press releases
Subscribe
Financial calendar
Analysts
Prospectus archive
Certified Adviser
IR contact
Media
Press releases
Image bank
Subscribe
Media contact
Contact
IR contact
Media contact
Certified Adviser
Search for:
July 9, 2012
Non Regulatory
InDex publish positive results from Kappaproct Compassionate Use program
Documents
InDex publish positive results from Kappaproct Compassionate Use program
Investor contact
Johan Giléus
+46 8 122 038 50
[email protected]
SVE
ENG
SVE
ENG
